Actively Recruiting
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Led by Hansoh BioMedical R&D Company · Updated on 2024-12-02
220
Participants Needed
21
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
CONDITIONS
Official Title
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 years or older
- Histologically or cytologically confirmed relapsed, locally advanced, or metastatic esophageal carcinoma or other advanced solid tumor
- At least one measurable lesion outside of cavity structures according to RECIST 1.1
- Agree to provide fresh or archival tumor tissue and blood samples
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Estimated life expectancy greater than 12 weeks
- Agree to use medically accepted contraception methods
- Use adequate contraceptive measures throughout the study
- Female participants must not be pregnant at screening or have evidence of non-childbearing potential
- Signed and dated informed consent form
You will not qualify if you...
- Previous or current treatment with B7-H3 targeted therapy
- Any cytotoxic chemotherapy, investigational agents, anticancer drugs within 14 days before first dose
- Prior treatment with a monoclonal antibody within 28 days before first dose
- Local radiotherapy for palliation within 2 weeks before first dose or more than 30% bone marrow irradiation
- Large-scale radiotherapy within 4 weeks before first dose
- Major surgery within 4 weeks before first dose
- Previous or concurrent malignancies
- Significant tumor invasion into adjacent organs (aorta or trachea) increasing bleeding or fistula risk
- Inadequate bone marrow reserve or organ dysfunction
- Evidence of cardiovascular risk
- Current severe or uncontrolled systemic diseases
- Mucosal or internal bleeding within 1 month before first dose
- Severe infections within 4 weeks before first dose
- Active infectious diseases such as hepatitis B or C before first dose
- History of neuropathy or mental disorders
- Pregnant or lactating females
- History of severe hypersensitivity or infusion reactions to HS-20093 or related drugs
- Vaccination or hypersensitivity within 4 weeks before first dose
- Unlikely to comply with study procedures or requirements
- Any condition compromising safety or interfering with assessments as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
2
Fujian Provincial Tumor Hospital
Fujian, Fujian, China, 350014
Not Yet Recruiting
3
The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army
Fuzhou, Fujian, China, 350014
Actively Recruiting
4
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510000
Actively Recruiting
5
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 1540000
Actively Recruiting
6
Tumour Hospital of Anyang city
Anyang, Henan, China, 455000
Actively Recruiting
7
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China, 471003
Actively Recruiting
8
Nanyang Central Hospital
Nanyang, Henan, China, 422000
Actively Recruiting
9
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453100
Actively Recruiting
10
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
11
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
12
Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
13
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Not Yet Recruiting
14
Nantong Tumor Hospital
Nantong, Jiangsu, China, 226300
Actively Recruiting
15
Jiangyin People's Hospital
Wuxi, Jiangsu, China, 214400
Actively Recruiting
16
Jiangxi Provincial Tumor Hospital
Nanchang, Jiangxi, China, 330038
Not Yet Recruiting
17
Liaoning Cancer Hospital
Shenyang, Liaoning, China, 110000
Actively Recruiting
18
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110002
Actively Recruiting
19
Affiliated Hospital of Jining Medical University
Jining, Shandong, China, 272000
Not Yet Recruiting
20
Sichuan Cancer Hospital&Institude, Sichuan Cancer Center,Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China
Chengdu, Sichuan, China, 610041
Actively Recruiting
21
The Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 830011
Actively Recruiting
Research Team
Y
Yun Sun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here